Press Releases
- Navitor Pharmaceuticals Announces Janssen Has Acquired Anakuria Therapeutics, Inc.
- Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138
- Navitor’s Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in Depression